|
![]() |
|
|
Interferon_gamma-1b: profile and news
PR Newswire (press release), HCV) infections. The pulmonology portfolio includes Actimmune(R) (interferon gamma-1b), pirfenidone and research programs. Actimmune ... InterMune Announces Divestiture of Oritavancin Dec 27, 2005 Yahoo! News (press release) HCV) infections. The pulmonology portfolio includes Actimmune® (interferon gamma-1b), pirfenidone and research programs. Actimmune ... -> InterMune Announces First Quarter Financial Results and Business ... Apr 27, 2006 InterMune to Present at the Deutsche Bank 2006 Health Care ... Apr 26, 2006 Other information Indication For treatment of Chronic granulomatous disease, Osteopetrosis Pharmacology IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring. Mechanism Of Action Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes. Drug Category Antiviral Agents; Immunomodulatory Agents Brand Names/Synonyms Interferon gamma precursor;IFN-gamma;Immune interferon; Actimmune (InterMune Inc) Dosage Forms Not Available Absorption Not Available Interactions Not Available Chemical IUPAC Name Human interferon gamma-1b Chemical Formula C761H1206N214O225S6 Half Life Not Available Drug Type Approved Drug # Accession No BIOD00017 CAS Registry Number 82115-62-6; 98059-61-1 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |